Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States
Clinical trial NCT06161051 · COMPLETED
Trial details
- NCT number
- NCT06161051
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-10-03
- Primary completion
- 2022-11-02
- Enrollment
- 287
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.